Gyroscope Targeting ‘Huge’ Population With Dry AMD Gene Therapy
Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment
You may also be interested in...
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker